Key Points for Decision Makers {#FPar1}
==============================

In the field of cancer, health technology assessment (HTA) evaluations can be restricted due to limited comparative clinical evidence and high cost.A comparison between three international HTA agencies for novel lung cancer therapy evaluations demonstrated a low listing success rate across Australia, Canada and England.This analysis identified major uncertainties within the HTA agencies. International solutions may include better use and evaluation of the managed entry schemes and the establishment of international registries.

Introduction {#Sec1}
============

After cardiovascular disease, cancer is the second most common cause of death globally \[[@CR1]\]. In 2013, cancer was responsible for 8.2 million deaths, with 196.3 million years of health life lost due to illness, disability and death (DALYs) \[[@CR2]\]. Lung cancer remains the leading cause of death among all cancer types. In 2009, the European Union (EU) estimated the cost of cancer care at €126 billion per annum, with lung cancer causing the most significant economic burden \[[@CR3]\]. Of this, only €51 billion was accounted for by the EU healthcare system, while the remaining 60% was the result of factors such as loss of productivity and working days, and early death. These data suggest that direct costs should not represent the focus of healthcare policies, as the economic burden extends beyond the boundaries of the healthcare system. Given the above economic concerns, lung cancer in particular is a good case study because of the extensive involvement of personalised medicine in the treatment options.

In the field of cancer, health technology assessment (HTA) evaluations can be restricted due to limited comparative clinical evidence with short-term efficacy results. In addition, the high cost of cancer treatment raises the stakes and may further complicate the HTA appraisal process. For example, early reimbursement for a medication, with undeveloped evidence, may later prove to have only marginal benefit and result in exorbitant opportunity cost. The high uncertainty that can necessitate a lengthy decision-making journey may result in delays in patients' access to treatment. In a large international study comparing the success of access to new oncology medicines across five countries (Australia, Canada, England, Germany and France) over a 5-year period \[[@CR4]\], new listings were highest in France and Germany, at a similar level in Canada and Australia, and the lowest in England. The mean time from registration to listing was longer for Australia and England than in most other countries. In a similar study, researchers assessed the HTA recommendations for medications used in five cancer sites, including lung cancer, over almost 10 years \[[@CR5]\]. Canada had a higher positive recommendation rate (95%) when compared with the United Kingdom (UK) (48%). For the former, recommendations were always accompanied by special pricing arrangements.

The recent and rapid development of novel therapies in lung cancer has increased the pressure within HTA agencies around the world. A comparison between the HTA agencies will help to explain the major uncertainties from the agency's perspective and to identify the best natural course for their recommendations. The objective of this study was to compare the listing success rate and time incurred to listing of recently approved lung cancer medications across three countries (Australia, Canada and England), based on HTA documents. Major uncertainties and limiting factors, reported throughout said documents (effectiveness and economic analysis), that compromise HTA recommendations were identified.

Methods {#Sec2}
=======

A stepwise approach was followed. First, the United States Food and Drug Administration (US FDA) databases were reviewed to identify lung cancer medications approved between 2013 and 2016 \[[@CR6]\]. Since the first immunotherapy was approved in 2013, this timeframe was considered adequate for the data cut-off in the study. Second, publicly available documents from HTA agencies for the three countries were reviewed. The selected countries were Australia, Canada and England, based on the fact that they use the English language and have wide geographical distribution. The HTA Agencies for these countries are as follows:The Pharmaceutical Benefits Advisory Committee (PBAC) in Australia \[[@CR23]\].The Pan Canadian Oncology Drug Review (pCODR), which can be accessed through The Canadian Agency for Drugs and Technologies in Health (CADTH) website in Canada \[[@CR28]\].The National Institute of Health and Care Excellence (NICE) in England \[[@CR35]\].

The data retrieval cut-off point was September 2016 for the three HTA agencies. A comparison between the three countries was performed, with respect to listing status and differences in recommendations for cost effectiveness. Only initial and final recommendation drafts were reviewed. Other documents, such as the original submissions, were omitted as some were not available online or consistently across the three jurisdictions. Medications that were originally listed in a country before 2013 were excluded from the analysis. The results were analysed and are presented as total figures, owing to the small sample size. The analysis was classified into four major sections to detect key arguments within the summary documents, namely listing success rate; time incurred to access medications; effectiveness and economic analysis; and deferral or rejection recommendations by the HTA agencies' analysis.

Listing Success Rate {#Sec3}
--------------------

For listing status, medications were classified into three categories: first, 'listed', which represents medications recommended by the HTA and reimbursed; second, 'not listed', which indicates medications that are not recommended or are rejected by the HTA; third, 'no submission/under review', which denotes medications that have either had no HTA submission or were pending HTA agency review. The success rate was estimated from the total number of listed medications divided by the total number of medications reviewed by the HTA agency for each country.

The analysis also included other information pertinent to the listing process within the country for each medication, including number of submissions, feasibility of the 'priority review process' and the presence of any 'access programme'.

Time Incurred to Listing {#Sec4}
------------------------

To simplify the analysis, the data were classified into three parts: 'time from registration to outcome', 'time from HTA submission to outcome' and 'time from HTA outcome to listing'. However, only the 'time from submission to outcome' data were presented in this analysis because it was considered more pertinent and valuable, as it reflects the actual time required for the HTA review process.

Registration represents the market authorisation, while the HTA's outcome represents the HTA's listing recommendation and the listing represents the actual implementation of 'reimbursement'. Registration dates were obtained from Therapeutic Goods Administration (TGA) in Australia, Health Canada in Canada, and European Medicines Agency (EMA) or Medicines and Healthcare Products Regulatory Agency (MHRA) in England. As MHRA and EMA's approval dates were close, the latter were chosen. In Australia, all submissions to the PBAC were evaluated within the meeting cycles (every 3 months). Accordingly, the date of PBAC submission was assumed to be 3 months before the PBAC meeting cycle, unless specified in the summary documents. Listing date (reimbursement) was obtained from the PBS website for Australia. In Canada, after the positive recommendations for listing, the actual listing process varies between provinces and negotiation on pricing takes place within the pan-Canadian Pharmaceutical Alliance (pCPA); Ontario was selected to represent the actual implementation date. It was noted that in that province, listings were always considered earlier than in other provinces. Despite that, it was selected because it is one of the major provinces for cancer care. In England, while NICE always recommends within 3 months for reimbursement, we were unable to locate an official site with a clear implementation date. The listing dates were therefore obtained from a general web search.

Effectiveness and Economic Analysis {#Sec5}
-----------------------------------

Data collected from effectiveness and economic recommendations were presented as a descriptive analysis. The major points considered were adopted from European Network for Health Technology Assessment (EUnetHTA) recommendations for relative effectiveness assessments (REA) of pharmaceuticals \[[@CR7]\]. All captured sources of uncertainty within the summary documents between the nations were standardised to simplify and facilitate the analysis (Table [1](#Tab1){ref-type="table"}).Table 1Examples for the major standardised uncertainties in the effectiveness and economic analysisStandardised uncertaintiesExample**Effectiveness analysis**Clinical evidence statusLimited or immature evidenceUse of indirect comparisonComparison of clinical results across different interventionsUse of response rate as a surrogate marker for survivalIn case of absence of progression-free survival (PFS) or overall survival (OS) resultsCorrelation to the country's population/practiceIf existing practice has multiple possible comparators or population demographics**Economic analysis**Limited clinical efficacy dataDraw a cost-effectiveness conclusion from limited non-comparative efficacy studiesChoice of the economic comparator in submissionsComparators that were used for the economic analysisCo-dependent technologyMutation testing status, which includes the role, threshold, listing and screening statusTime horizon reconsiderationTruncation of time horizon from 10 to 5 yearsExtrapolation methodWhen extrapolating for survival beyond the duration of clinical trialsTreatment durationTreatment duration beyond disease progressionTreatment benefitExtent of treatment benefit beyond cessation of treatmentHealth utilities or resources estimatesWhen the value calculated may not reflect those observed values in previous studiesCorrelation to the country's population/practiceIf practice has multiple choices for comparator such as in Canada, where comparators may differ across Canadian provinces. Population could be Asian versus non-Asian

Reasons for Deferral or Rejection of Recommendations by the HTA Agencies' Analysis {#Sec6}
----------------------------------------------------------------------------------

Data were collected from the initial and final recommendations for each medication across the three countries. Medications that were rejected or differed in the initial or final assessments were reviewed to list the main points addressed by the HTA for rejections. Data were extracted verbatim from the HTA documents.

Results {#Sec7}
=======

A total of 11 medications, in 12 indications, were identified as recently FDA-approved agents for lung cancer treatment within the last 4 years (Table [2](#Tab2){ref-type="table"}). Two medications (erlotinib and gefitinib) were excluded because they had been listed earlier than 2013 in some of the countries. The final analysis involved 9 medications with 12 indications. The national registration of all indications within the three countries was in line with the FDA approval criteria, except for crizotinib. National registration under TGA in Australia and Health Canada for crizotinib was general for all lines of treatment for patients who are anaplastic lymphoma kinase (ALK) positive. However, the EMA specified the line of therapy in its registration (first- versus second-line therapy) with a 3-year gap in between for each line of therapy. At the time of the HTA agency evaluations, a distinction was also made between first- and second-line therapies for crizotinib, for which separate submissions were required in all three countries.Table 2Registration and listing summary for the selected lung cancer medicinesMedicationFDA approval date \[[@CR6]\]Registration dateHTA agencies outcome dateActual listing/implementation dateTGA Australia \[[@CR19]\]Health Canada \[[@CR20]\]MHRA/EMA^a^ England \[[@CR21], [@CR22]\]PBAC Australia \[[@CR23]\]pCODR Canada \[[@CR28]\]NICE England \[[@CR35]\]AustraliaCanada (Ontario)EnglandCrizotinib ALK-positive (general)^b^20/11/2013Orphan: 05/09/201127/9/201325/04/2012NANANot listed04/10/2012 \[[@CR29]\]NANANANA ALK-positive (first-line)NANANA25/11/2015NSListed21/07/2015 \[[@CR30]\]Reconsidered 17/07/2016 \[[@CR36]\]NA04/12/2015 \[[@CR40]\]NA ALK-positive (second-line)NANANA23/10/2012Listed01/11/2014 \[[@CR24]\]Listed02/05/2013 \[[@CR31]\]Not listed 13/08/2013Reconsidered 17/07/2016 \[[@CR37]\]01/07/201501/10/2013 \[[@CR41]\]NA ROS1-positive11/03/2016NRNRNRNSNSNSNANANAAlectinib11/12/2015Orphan: 27/10/2015NRNRNSNSURNANANANecitumumab24/11/2015NRNR25/02/2016NSNSURNANANAOsimertinib13/11/201503/08/201605/07/2016^c^02/02/2016NSURURNANANANivolumab09/10/201511/01/201626/02/201601/10/2015Not listed01/03/2016 \[[@CR25], [@CR26]\]Listed03/06/2016 \[[@CR32]\]URNAUNNAPembrolizumab02/10/2015NR01/04/2016^c^23/06/2016NSURURNANANARamucirumab12/12/201423/07/2015NR18/12/2015NSURURNANANACeritinib29/04/2014Orphan: 01/09/201431/03/201627/03/201506/05/2015NSNot listed03/12/2015 \[[@CR33]\]Listed20/05/2016 \[[@CR38]\]NANA29/07/2016 \[[@CR43]\]Afatinib12/07/2013Orphan: 01/06/201207/11/201301/11/201325/09/2013Not listed01/07/2015 \[[@CR27]\]Listed2/05/2014 \[[@CR34]\]Listed17/03/2014 \[[@CR39]\]NA19/08/2014 \[[@CR42]\]NA*ALK* Anaplastic lymphoma kinase, *EMA* European Medicines Agency, *FDA* US Food and Drug Administration, *HTA* health technology assessment, *MHRA* Medicines and Healthcare Products Regulatory Agency, *NA* not applicable/not available, *NICE* National Institute of Health and Care Excellence, *NR* not registered, *NS* no submission available, *PBAC* Pharmaceutical Benefit Advisory Committee, *pCODR* Pan Canadian Oncology Drug Review, *TGA* Therapeutic Goods Administration, *UN* under negotiation, *UR* under review^a^Authorisation date according to EMA^b^General approval for ALK-positive, line of therapy is not indicated^c^Date for positive decision

For all countries, a process existed for a 'priority review process', whereby the submission of a new technology could be performed before, or at the same time as national registration. This process is identified as a 'parallel process' in Australia and as a 'pre-NOC (notice of compliance)' procedure in Canada. A similar system is operated in England. All indications that were approved were reimbursed through an 'access programme' and featured pricing arrangements. It was noted, however, that such an access programme was not specified within the documents in Canada.

Listing Success Rate {#Sec8}
--------------------

Overall, Canada had the highest listing success rate of 33%, versus 17% in England and 8% in Australia at the time of the study (the HTA process was not final for only one submission). In addition, Canada reviewed more indications than the other two countries (six versus three apiece) (Fig. [1](#Fig1){ref-type="fig"}). The majority of indications (≥ 50%) had not been submitted or were under review by the HTA agencies.Fig. 1Listing success rate comparison across countries. *PBAC* Pharmaceutical Benefit Advisory Committee, *pCODR* Pan Canadian Oncology Drug Review, *NICE* National Institute of Health and Care Excellence

Time Incurred to Listing {#Sec9}
------------------------

Overall, the HTA review process in terms of 'time from submission to outcome' necessitates a lengthy duration of up to 2 years in Australia and England, whereas matters are more timely in Canada, taking up to 1 year. The time required for reimbursement (the 'time from HTA outcome to listing') was a minimum of 3 months for each country.

Effectiveness and Economic Analysis {#Sec10}
-----------------------------------

A summary of the effectiveness and economic recommendations for the submission process is detailed in Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}. The final analysis consisted of seven indications that had HTA submissions. The medications included were afatinib (two indications), crizotinib (three indications), and ceritinib and nivolumab (one indication each).Table 3Summary for effectiveness analysis across submissionsMedicationHTAHTA's nominated comparatorTrial's comparatorTrials consideredTrial typeIndirect analysis involvedPrimary outcomeOngoing trials consideredUncertaintyPBACpCODRNICEAfatinib (first-line)XCis-pemCis-gemerlotinib, gefitinibYesYesNoLUX-lung 3LUX-lung 6Phase IIIYesPFSLUX-lung 6 UpdateIndirect comparisonThe relation to Australian populationImmature survival data✓Cis-pemCis-gemerlotinib, gefitinibYesYesNoLUX-lung 3LUX-lung 6Phase IIIMTCYesPFSLUX-lung 7Limited evidence in comparison with other TKIIndirect comparisonThe relation to Canadian practice✓Erlotinib, gefitinibNoLUX-lung 3,LUX-lung 6Phase IIIMTCYesPFSLUX-Lung 7Indirect comparisonLimited evidence in comparison with other TKIThe relation to English populationImmature survival dataAfatinib (Exon 19 deletion)XGefitinib, erlotinibNoLUX-lung 3,LUX-lung 6Phase IIIMTCYesPFSLUX-lung 7Indirect comparisonLimited evidence with non-statistically significant results of the indirect comparisonsCeritinibXPemetrexedPlatinum doubletsDocetaxelBSCPlaceboNo comparator armASCEND-1ASCEND-2Single-arm Phase I/IINoORRASCEND 4ASCEND 5Limited evidence from non-comparative studiesResponse rate as a surrogate outcome for survival✓BSCNo comparator armASCEND-1ASCEND-2Single-arm Phase I/IIYesORRASCEND 5Limited evidence from non-comparative studiesIndirect comparisonCrizotinib (general)XMultiple: Chemotherapy (doublets/single)Anti-EGFR TKIPlaceboNo comparator armPROFILE 1001PROFILE 1005Single-armPhase I/IINoORRPROFILE 10014PROFILE 1007Limited evidence from non-comparative studiesResponse rate as a surrogate outcome for survivalCrizotinib (first-line)✓Multiple: Chemotherapy (doublets/single)PlaceboYesNoPROFILE 10014Phase IIINoPFSPROFILE 1029Immature survival dataCrizotinib (second-line)✓PemetrexedYesPROFILE 1001PROFILE 1005PROFILE 1007Single-armPhase I/II, Phase IIIYesORRPFSPROFILE 10014Immature follow-up✓Multiple: ChemotherapyAnti-EGFR TKIPlaceboYesNoPROFILE 1001PROFILE 1005PROFILE 1007Single-armPhase I/II, Phase IIINoORRPFSPROFILE 10014Update for PROFILE 1007Limited evidence in comparison with other TKIXDocetaxelBSCYesNoPROFILE 1007Phase III MTCYesPFSUpdate for PROFILE 1007Immature survival dataIndirect comparisonNivolumabXFor S:DocetaxelYesCheckMate 017CheckMate 057Phase IIIYesOSCheckMate 026The relation to Australian populationFor NS:PemetrexedNoDocetaxelYes✓For S:DocetaxelFor NS: PemetrexedYesNoCheckMate 017CheckMate 057Phase IIIMTCYesOSCheckMate 078Limited evidence from open label trialsIndirect comparisonLimited evidence in comparison with other anti-PD-L1X not listed, ✓ listed; *BSC* best supportive care, *EGFR* epidermal growth factor receptor, *HTA* health technology assessment, *MTC* multiple treatment comparisons, *NICE* National Institute of Health and Care Excellence, *NS* non-squamous, *ORR* overall response rate, *OS* overall survival, *PBAC* Pharmaceutical Benefit Advisory Committee, *pCODR* Pan Canadian Oncology Drug Review, *PD*-*L1* programmed death ligand 1, *PFS* progression-free survival, *S* squamous, *TKI* tyrosine kinase inhibitors Table 4Summary for economic analysis across submissionsMedicationHTASubmission's nominated comparatorTime horizonAnalysisSubmitted ICER (per QALY gained)^a^Calculated ICER (per QALY gained)^a^Cost-effectiveness resultUncertaintyPBACpCODRNICEAfatinib (first-line)XCis-gem5 yearsCUA\$45,000--\$75,000NACE at reduced priceThe co-dependent technologyThe relation to Australian populationExtrapolation methodHealth utility estimates✓Cis-pemGefitinibErlotinib10 yearsCUACEA\$25,069 versus cis-pem\$72,153 versus gefitinibVersus cis-pem:\$25,069Versus gefitinib:\$39,000--\$211,000CE versus cis-pemUnknown CE versus cis-gemCE versus gefitinib at reduced priceChoice of economic comparatorClinical efficacy dataResource estimationExtrapolation methodTime horizon reconsideration to 5 years✓ErlotinibGefitinib10 yearsCUA£10,302 versus erlotinib£17,933 versus gefitinib£23,700 versus cis-pem (non-Asian as a representative of England population)CE versus cis-pemThe relation to English populationExtrapolation methodAfatinib (Exon 19 deletion)XErlotinibGefitinib5 yearsCUAConfidentialNACannot be estimated on uncertainty of clinical dataExtrapolation methodThe relation to Australian populationClinical efficacy dataCeritinibXPemetrexedHistorical control^b^BSCDocetaxelNACUACEAVersus pemetrexed:\$80,100Versus historical control:\$104,436Versus BSC:\$149,117Versus docetaxel:\$149,780Versus pemetrexed:\$196,335--\$211,759Versus historical control:\$164,503--\$166,201Versus BSC:\$219,353--\$222,335Versus docetaxel:\$241,396--\$244,906Not CE based on uncertainty of clinical dataClinical efficacy dataExtrapolation methodHealth utility estimatesThe relation to Canadian practice✓BSC10 yearsCUA£62,500£79,500 and £99,700£50,000 with PASCE for end-of-life treatment with PASClinical efficacy dataTreatment durationTreatment benefitExtrapolation methodHealth utility estimatesCrizotinib (general)XStandard of care^c^Pemetrexed6 yearsCUACEAConfidentialIf crizotinib first-line:\$240,972--\$255,976 versus standard of careNot CE based on uncertainty of clinical dataClinical efficacy dataThe co-dependent technologyTime horizon reconsideration to 2 yearsTreatment benefitExtrapolation methodCrizotinib (first-line)✓Standard of care^d^6 yearsCUACEA\$153,597\$173,570--\$285,299CE at reduced priceTime horizon reconsideration to 4 yearsTreatment benefitExtrapolation methodThe co-dependent technologyCrizotinib (second-line)✓PemetrexedNACUA\$45,000--\$75,000\$105,000--\$200,000CE through Managed Entry Scheme (MES)Clinical efficacy dataExtrapolation methodTreatment benefitThe co-dependent technology✓Pemetrexed5 yearsCUACEAConfidential\$140,561--\$216,050CE at reduced priceHealth utility estimatesTime horizon reconsideration to 3 yearsThe co-dependent technologyExtrapolation methodXDocetaxelBSC15 yearsCUA£65,925 versus docetaxel£47,914 versus BSC\> £100,000 versus docetaxel\> £50,200 versus BSCNot CE based on uncertainty of clinical dataIndirect analysisHealth utility estimatesExtrapolation methodNivolumabXDocetaxel10 yearsCUA\$45,000--\$75,000\$75,000--\$105,000 and \$105,000--\$200,000Could not be estimatedThe relation to Australian populationTime horizon reconsideration to 5 yearsExtrapolation methodHealth utility estimatesResources estimationTreatment durationChoice of economic comparator✓S:DocetaxelPemetrexedErlotinibNS: Pemetrexed10 yearsCUACEAVersus docetaxel:S: \$151,560NS: \$133,520Versus docetaxel:S: \$193,918--\$219,660NS: \$183,386--\$236,851CE at reduced priceChoice of economic comparatorTime horizon reconsideration to 5 yearsExtrapolation methodTreatment durationHealth utility estimatesX not listed, ✓ listed, *BSC* best supportive care, *CE* cost effectiveness, *CEA* cost-effectiveness analysis, *CUA* cost-utility analysis, *HTA* health technology assessment, *ICER* incremental cost-effectiveness ratio, *NA* not applicable/not available, *NICE* National Institute of Health and Care Excellence, *NS* non-squamous, *PAS* patient access scheme, *PBAC* Pharmaceutical Benefit Advisory Committee, *pCODR* Pan Canadian Oncology Drug Review, *QALY* quality-adjusted life-years, *S* squamous^a^ All reported ICER for PBAC are in Australian dollar, for pCODR in Canadian dollar, for NICE in British pound^b^ Canadian historical controls: a combination of treatment found through a chart review of patients treated with crizotinib which represented six oncology centers across Canada^c^ Standard of care: 1st-line cis-gem followed by 2nd-line pemetrexed and 3rd-line erlotinib^d^ Standard of care: 1st-line pemetrexed-platinum followed by 2nd-line crizotinib and 3rd-line docetaxel

### Effectiveness Analysis {#Sec11}

Most of the HTA-nominated comparators in the efficacy analysis varied across the agencies for the same technology and indication (Table [3](#Tab3){ref-type="table"}). Different comparators were used for nine of the ten submissions (90%) across countries for indications that were assessed by at least two nations. It was also noted that even if the technology was submitted within the same time interval, with almost universally accepted international standard practice, the comparators sometimes differed between agencies; for example, regarding the nivolumab and afatinib submissions. Several comparators used were similar to those employed in the registration trials. Most comparators included were considered to be relevant to national or standard disease practice. In submissions that included trials with a comparator arm, eight out of nine (\~ 90%) submissions involved additional comparators that differed from those used in the registered trials. For example, in the case of afatinib, epidermal growth factor receptor (EGFR) inhibitors were added to the comparator list, together with chemotherapy; however, only the latter was used as the comparative arm in the registered trials as a standard of care at the time of the study.

The choice of comparators for NICE relied substantially on current clinical practice in England, which included non-listed technologies or, sometimes, best supportive care as in the case of ceritinib. By contrast, a comparator that is not subsidised by the PBS will not be proposed as a comparator by PBAC in Australia. Finally, a greater number of comparators were selected in Canada due to variations in current accepted practices between Canadian provinces. Afatinib is the best example of how the choice of comparators and final recommendations differed according to funding status in the various Canadian provinces. The final cost-effectiveness decision was different across Canadian provinces according to the choice of the comparator and practice within each province. Consequently, due to discrepancies in comparators between trial data and HTA evaluations across the three countries, analyses were indirect for the efficacy evaluation (\~ 70%).

Registration trials that were accepted in the submissions were mostly phase III trials with the primary outcome of survival, either progression-free survival (PFS) or overall survival (OS) (75%), or phase I/II trials with no comparator arm (25%). Undeveloped clinical data (including survival, safety or quality of life) in ongoing trials were considered and discussed in all summary documents for future deliberation. Uncertainty regarding the evaluated data related mostly to indirect analysis (46%), or limited (53%) or immature (38%) evidence.

Approximately 30% of the submissions involved uncertainty about the technology's applicability to either the country's population or practice. Another factor associated with uncertainty within the submissions was the use of the disease response rate as a surrogate marker for survival if the early phase I/II trials had been accepted with no comparator arm. Only one out of three submissions were recommended and listed by the HTA with no comparator arm or survival evidence; namely, the NICE evaluation for ceritinib.

### Economic Analysis {#Sec12}

Comparators used for economic evaluations (Table [4](#Tab4){ref-type="table"}), among others nominated for the efficacy assessment, were limited to the current national listed/reimbursed alternatives used for the same indication. For example, in Canada, erlotinib and gefitinib were nominated as a comparison against the effectiveness of afatinib; however, only gefitinib was included in the economic analysis because erlotinib was not funded as a first-line therapy at the time of evaluation.

Survival extrapolations for the economic evaluation were applied (\~ 100%) to all evaluated submissions in this study. Of the 13 submissions, eight (62%) had a horizon of \> 5 years, three (23%) used a 5-year horizon and two were not reported (15%). All submissions that used a horizon of \> 5 years in their economic analysis were reconsidered and readjusted by the HTA agency, except for submissions to NICE. In general, the incremental cost-effectiveness ratio (ICER) was required to be recalculated by the HTA agencies in most of the cases. When that was done, the new ICER was always higher (14 of the 15 economic analyses, \~ 95%) than that proposed by the company in the initial submission.

The final decisions on cost effectiveness taken by the agencies could not be determined in three of the 15 (20%) economic analyses for different comparators within submissions. Indications were considered cost effective in only two of the 15 analyses (13%), cost effective at a reduced price or within a special programme in seven of the 15 (47%) and not cost effective in three of the 15 (20%). Of the 13 submissions, uncertainty was identified in relation to extrapolation methods in 13 (100%), health utility estimates in seven (54%), co-dependent technologies in five (38%), relation to country practice or population in four (30%), treatment benefit in four (30%), treatment duration in three (23%) and resource estimation in two (15%). In the submitted analyses, uncertainty identified by the agency in relation to the choice of comparators pertained either to missing data or dropouts, as represented in three of the 13 submissions (23%).

Deferral or Rejection of Recommendations by the HTA Agencies' Analyses {#Sec13}
----------------------------------------------------------------------

In Table [5](#Tab5){ref-type="table"}, major similarities were identified across HTA agencies and indications. There was uncertainty regarding the clinical evidence due to immature or limited data, together with unresolved discussions (such as limitations, uncertainties and draw backs) on ongoing trials. NICE was the only agency that proposed a future review, regardless of the final recommendations. Reviews were considered in terms of the updated clinical data and for regulatory and access situations. For example, where crizotinib was earlier rejected by NICE, ceritinib was later approved for ALK-positive non-small cell lung cancer (NSCLC) in patients who failed crizotinib. The latter was not available within the NHS at that time and is currently administered through the Cancer Drugs Fund. Therefore, there was a subsequent review of ceritinib, after its approval was proposed by NICE, for when crizotinib is no longer managed by said Fund.Table 5Overview of submissions' deferral/rejection recommendationsMedicationsPBAC (Australia)pERC (Canada)NICE (England)Afatinib*First submission (second/third*-*line):* Requested listing was outside the TGA indication Unaccepted economic approach due to the weakness of the clinical claim*Second submission (first*-*line):* Not cost effective, request for Risk Share Arrangement (RSA)*Third submission (first*-*line with restriction for exon 19 deletion):* Rejected due to inadequate evidence The restricted indication to exon 19 is not consistent with previous PBAC, US guidelines*Initial recommendations:* Uncertainty in clinical benefit and cost effectiveness compared with other EGFR inhibitors Waiting for the ongoing comparative LUX-Lung 7 trial*Final recommendations:* Recommended but not for all Canadian provinces because of different cost-effectiveness decisionsCeritinib*Initial and final recommendations:* Not recommended because of limited evidence Waiting for ongoing (phase III) ASCEND 4 and ASCEND 5 trials*Final appraisal 1:* Not recommended because of limited evidence Not cost effective with high ICER Waiting for ongoing (phase III) ASCEND 5 trial*Final appraisal 2:* Recommended with discount agreed in the patient access scheme (PAS)Crizotinib*First submission (second*-*line):* Deferred twice for price reduction to achieve an acceptable cost-effectiveness ICER Immature survival data from PROFILE 1007 trial*Final submission (second*-*line):* Recommended through managed entry scheme (MES) List ALK mutation testing*First submission (general indication):* Not recommended because of limited evidence Unable to estimate cost effectiveness Uncertainty around ALK-testing screening cost Waiting for ongoing trials PROFILE 1007/10014*Resubmission recommendations:* Recommended with two separate submissions for ALK-positive (first-line and second-line therapy) Establish a routine ALK mutation testing*Final appraisal (second*-*line):* Not recommended as it is not cost-effective Immature survival data from PROFILE 1007 trial and the impact of crossover design in the study The access and cost of ALK testing in the UKNivolumab*First submission:* Economic analysis was not adequately demonstrated Requested more restriction inclusion criteria Status of PD-L1 testing in Australia Advice for financial cap due to uncertainty of the estimated net cost*ALK* Anaplastic lymphoma kinase, *EGFR* epidermal growth factor receptors, *ICER* incremental cost-effectiveness ratio, *NICE* National Institute of Health and Care Excellence, *PBAC* Pharmaceutical Benefit Advisory Committee, *PD*-*L1* programmed death ligand 1, *pERC* Pan-Canadian Oncology Drug Review (pCODR) Expert Review Committee, *TGA* Therapeutic Goods Administration

Other major points related to mutation testing as a co-dependent technology. The uncertainty around the initial cost-effectiveness decision for the indications evaluated constituted the major obstacle to its listing. Finally, cost effectiveness was always considered in terms of the provision of a discount or price reduction. Usually, a medication is recommended in conjunction with the use of a risk-sharing arrangement, like the managed entry scheme (MES) in Australia or the patient access scheme (PAS) in England.

Minor differences related to the regulatory processes or treatment guidelines within each country, as was the case with afatinib. The main issue with the initial submission of this drug in Australia was that the requested indication was outside the TGA-approved indication. However, the requested restriction was not consistent with the national and international guideline recommendations for the second submission.

Discussion {#Sec14}
==========

The listing success rate for lung cancer treatment, as a reference case, was found to be low across all three countries under investigation: 33% for Canada, 17% for England and 8% for Australia. This means that more than half of the technologies had no HTA submission yet or were under review by the HTA agencies at the time of this review. In general, Canada was further ahead in the listings rate and numbers of submissions appraised, and has a shorter HTA review process of \< 1 year, compared with Australia and England. All three countries have a priority review process whereby the HTA submission could be performed at the same time as national registration. Within the effectiveness analysis, 90% of submissions involved additional comparators that differed from those used in the registered trials. Across the HTA agencies' reviews, comparators were either dissimilar or altered for effectiveness and/or economic analysis for the same indication. Overall, immature or limited evidence was apparent for all indications, and uncertainties formed due to indirect analyses (70%) and survival extrapolation (100%). Within the economic evaluation, a readjusted time horizon and recalculated ICER were frequently proposed by the HTA agencies in all three countries. The submitted time horizon was usually \> 5 years (62%), while the newly recalculated ICER was invariably higher (95%) than that proposed by the drug company. Final recommendations for NICE are consistently accompanied by a future review for evidence and regulatory access updates. Despite most of the indications being deemed not cost effective, they were subsequently listed (47%) at a reduced price and/or with a country companion-specific access programme. In addition, the status of national mutation test listing was a common theme for the initial recommendations by all HTAs. Despite the small size of this study, a similar analysis demonstrated higher positive recommendations for oncology drugs by Canada when compared with the UK \[[@CR5]\].

Within this study, indirect analysis and extrapolation created substantial uncertainties surrounding the efficacy and economic evidence. The approval of medications based on preliminary clinical evidence is clearly more prominent in cancer than in other specialties. These common inherited uncertainties in the cancer field are bound to persist and place pressure on stakeholders. The 'trade-off' is geared towards early access with a consideration of evidence development, which, in broad terms, is not the case in this analysis \[[@CR8]\]. It was observed that more rejections and deferrals for technologies were seen than accepting with an access program.

A variety of global regulatory mechanisms have been introduced to overcome these uncertainties. First, to expedite registrations for treatment of diseases with unmet medical needs, early registration of innovative medicines was launched by several market-authorisation agencies, such as Breakthrough Therapy Designation (BTD) by the FDA in 2012 and PRIority Medicine (PRIME) by the EMA in 2016 \[[@CR9], [@CR10]\]. In this analysis, registration status seemed to have an implication in delaying access, irrespective of the currently available priority review processes. Afatinib, for example, had three unsuccessful submissions for listing in Australia, as a result of a wide range of national registration matters, including TGA-proposed indication and status of the TGA application.

Emerging schemes include performance-based risk-sharing arrangements for early access, which support the concept of providing additional benefit and value for money or 'coverage with evidence development' (CED) \[[@CR11]\]. These schemes may better serve the HTA agencies by sharing the financial risk owing to clinical uncertainty with the manufacturer. These agreements have been widely accepted under a variety of names across countries. The programmes linked to this study include the MES as a risk-sharing arrangement (RSA) in Australia and the PAS in the England. Canada has no such programs but has a different scenario, namely the NOC/c (notice of compliance with conditions), while a more recent development is 'Vanessa's Law' in 2013 \[[@CR12]\]. In respect to each specific programme, there are several measures mandated for their establishment. This was recently debated by several countries, including Canada \[[@CR13]\]. Some general measures, such as a data collection plan (registry), electronic health records (EHRs), a design and enforce discount, and an authority and ability to de-list, have all been nominated. Europe, for example, launched the 'Get Real' project in 2013 to collect and synthesise real-world evidence (RWE), which could be adopted earlier in pharmaceutical research and development (R&D) and the healthcare decision-making process \[[@CR14]\]. However, an estimation of the impact of these access programmes on HTAs requires further evidence of their effectiveness.

In general, in this study, HTAs mostly identified a higher ICER than that submitted by the company and subsequently requested a price reduction regardless of implementing RSA. It would appear that negotiation strategies of companies to initially request a high medication price may contribute to the delay in patient access. As such, HTA agencies could further consider mechanisms that encourage companies to offer a lower price earlier in the HTA process to enhance early patient access.

The HTA agency's selection of comparators will influence the ICER and, subsequently, the cost-effectiveness recommendations. Time is a very sensitive factor in deciding comparators in cancer treatments, where registered comparative studies have a comparator arm that might not be the standard of care at the time of subsequent HTA evaluation. As in the case of afatinib, the registered studies used a chemotherapy doublet as a comparator, while erlotinib and gefitinib were nominated by the agencies as the standard of care for patient treatment with EGFR mutation. In addition, matters are more uncertain for medications used in palliative settings, where the registered trial has no comparator arm. Accordingly, it is a challenge for the drug company to identify the comparator in the technology submission, and it may further encounter uncertainty for the comparator nominated by the HTA's reviewers. The comparator choice is influenced by multiple factors, which could include ethical, social or even equity dilemmas, as in the case of ceritinib. The situation may not be the same for drugs other than antineoplastics, as shown in various studies where comparators were found to be similar for Australia and Canada for 25 products reviewed, of which only two were cancer medications \[[@CR15]\].

When one study compared market access for lung cancer medications, access to biomarker testing was one of the major limitations when it came to comparing the performance of Canada and Latin America \[[@CR16]\]. This was also, informally, one of the reasons for delaying the listing of medications across the three countries assessed in this study. Some of these tests are not yet settled internationally, with concerns over the comparability of various assays, which will consequently compromise access at the national level. One of the latest examples is the PD-L1 (programmed death ligand 1) immunostaining test, which has different thresholds and target cells (i.e. tumour cells, immuno-infiltrating cells). Pembrolizumab, in frontline treatment for NSCLC, has just been published as having a survival benefit in PD-L1-positive patients \[[@CR17]\]. This was forecast to be the next standard of care with the adoption of the PD-L1 screening practice by many experts. Given the complexities of biomarker testing as a companion diagnostic, a 'blueprint proposal' is now being developed by the pharmaceutical and diagnostic companies to establish an evidence-based diagnostic characteristic for PD-L1 \[[@CR18]\]. As such, a potential aid will further facilitate countrywide access to these tests as a predictive biomarker for the new medications.

A limitation of the analysis is that the analysis was performed on lung cancer medications and cannot be extrapolated to other disease sites. Also, the analysis was limited to only three countries, but there are other HTA agencies that review cancer drugs.

Conclusion {#Sec15}
==========

This analysis demonstrated a low listing success rate for novel lung cancer therapies internationally within different HTA jurisdictions. Major uncertainties that are resistant to available solutions, such as managed access programmes, seem to be common across different countries. International solutions for major uncertainties may include better use and evaluation of managed entry schemes currently in play and/or further research into the design of better schemes. In addition, international collaboration among HTA agencies to establish data collection strategies will enhance larger and potentially more valuable registries.
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